Evaluation of the specific bacteriophages to control of E.coli
Not Applicable
- Conditions
- rinary tract infection.Urinary tract infection, site not specifiedN39.0
- Registration Number
- IRCT20190624043991N14
- Lead Sponsor
- Tehran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 20
Inclusion Criteria
Patients with recurrent urinary tract infections more than 3 positive cultures per year with E.coli
Age range 20-70 years
Consent to participate in the study
Exclusion Criteria
pregnant women
Patients with allergies
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rinary bacteria in patients with antibiotic-resistant urinary tract infections. Timepoint: Twice a week for three consecutive months. Method of measurement: Collect patients' urine samples and check the bacteria count.;Frequent urination in patients with antibiotic-resistant urinary tract infections. Timepoint: Twice a week for three consecutive months. Method of measurement: Collect patients' urine samples and check the bacteria count.;Dysuria in patients with antibiotic-resistant urinary tract infections. Timepoint: Twice a week for three consecutive months. Method of measurement: Collect patients' urine samples and check the bacteria count.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms do specific bacteriophages use to target and lyse antibiotic-resistant E. coli in UTIs (N39.0)?
How effective are bacteriophage therapies compared to standard-of-care antibiotics like fluoroquinolones in treating antibiotic-resistant E. coli UTIs?
Which biomarkers predict response to bacteriophage therapy in patients with N39.0 UTIs caused by antibiotic-resistant E. coli?
What are the safety profiles and adverse events associated with bacteriophage treatment for antibiotic-resistant E. coli UTIs (N39.0)?
Are there combination approaches involving bacteriophages and existing antibiotics for managing antibiotic-resistant E. coli UTIs (N39.0)?